BIOMAT Database Logo BIOMAT Database Logo

The early efficacy of topical levocabastine in patients with allergic conjunctivitis. 2006

Hiroshi Fujishima, and Kazumi Fukagawa, and Yoji Takano, and Shigeki Okamoto, and Yayoi Nakagawa, and Eiichi Uchio, and Norihiko Yokoi, and Atsuki Fukushima, and Etsuko Takamura
Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan. fhiroshi@sc.itc.keio.ac.jp

BACKGROUND We investigated the early efficacy of topical levocabastine, an H(1) histamine-receptor antagonist, in improving the clinical symptoms of allergic conjunctivitis. METHODS Thirty-six patients with allergic conjunctivitis were enrolled. One drop of levocabastine was instilled in one eye and one drop of artificial tears in the contralateral eye. Clinical examinations were performed before, and 15 and 30 minutes after instillation. Symptoms of itching and signs of injection were assessed at each time point. RESULTS Both levocabastine and artificial tears resulted in a statistically significant reduction in ocular itching. However, levocabastine was significantly more effective. CONCLUSIONS Although artificial tears had a positive effect in reducing symptoms of allergic conjunctivitis, by the washing out of allergens, levocabastine was more effective than artificial tears in controlling acute symptoms of allergic conjunctivitis, demonstrating that the selective H1 histamine-receptor antagonist action of levocabastine is rapidly effective in a clinical setting.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009883 Ophthalmic Solutions Sterile solutions that are intended for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS. Eye Drop,Eyedrop,Eyedrops,Ophthalmic Solution,Eye Drops,Drop, Eye,Drops, Eye,Solution, Ophthalmic,Solutions, Ophthalmic
D010880 Piperidines A family of hexahydropyridines.
D003233 Conjunctivitis, Allergic Conjunctivitis due to hypersensitivity to various allergens. Allergic Conjunctivitis,Conjunctivitis, Atopic,Conjunctivitis, Giant Papillary,Conjunctivitis, Vernal,Keratoconjunctivitis, Vernal,Allergic Conjunctivitides,Atopic Conjunctivitides,Atopic Conjunctivitis,Conjunctivitides, Allergic,Conjunctivitides, Atopic,Conjunctivitides, Giant Papillary,Conjunctivitides, Vernal,Giant Papillary Conjunctivitides,Giant Papillary Conjunctivitis,Keratoconjunctivitides, Vernal,Papillary Conjunctivitides, Giant,Papillary Conjunctivitis, Giant,Vernal Conjunctivitides,Vernal Conjunctivitis,Vernal Keratoconjunctivitides,Vernal Keratoconjunctivitis
D005260 Female Females
D006634 Histamine H1 Antagonists Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. Antihistamines, Classical,Antihistaminics, Classical,Antihistaminics, H1,Histamine H1 Antagonist,Histamine H1 Receptor Antagonist,Histamine H1 Receptor Antagonists,Histamine H1 Receptor Blockaders,Antagonists, Histamine H1,Antagonists, Histamine H1 Receptor,Antihistamines, Sedating,Blockaders, Histamine H1 Receptor,First Generation H1 Antagonists,H1 Receptor Blockaders,Histamine H1 Blockers,Receptor Blockaders, H1,Antagonist, Histamine H1,Classical Antihistamines,Classical Antihistaminics,H1 Antagonist, Histamine,H1 Antagonists, Histamine,H1 Antihistaminics,Sedating Antihistamines
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Hiroshi Fujishima, and Kazumi Fukagawa, and Yoji Takano, and Shigeki Okamoto, and Yayoi Nakagawa, and Eiichi Uchio, and Norihiko Yokoi, and Atsuki Fukushima, and Etsuko Takamura
Topical levocabastine versus sodium cromoglycate in allergic conjunctivitis.
August 1989, Allergy,
Hiroshi Fujishima, and Kazumi Fukagawa, and Yoji Takano, and Shigeki Okamoto, and Yayoi Nakagawa, and Eiichi Uchio, and Norihiko Yokoi, and Atsuki Fukushima, and Etsuko Takamura
Comparison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis. Study Group.
January 1998, European journal of ophthalmology,
Hiroshi Fujishima, and Kazumi Fukagawa, and Yoji Takano, and Shigeki Okamoto, and Yayoi Nakagawa, and Eiichi Uchio, and Norihiko Yokoi, and Atsuki Fukushima, and Etsuko Takamura
Ophthalmic levocabastine for allergic conjunctivitis.
April 1994, The Medical letter on drugs and therapeutics,
Hiroshi Fujishima, and Kazumi Fukagawa, and Yoji Takano, and Shigeki Okamoto, and Yayoi Nakagawa, and Eiichi Uchio, and Norihiko Yokoi, and Atsuki Fukushima, and Etsuko Takamura
A double-blind evaluation of topical levocabastine, a new specific H1 antagonist in patients with allergic conjunctivitis.
October 1985, Allergy,
Hiroshi Fujishima, and Kazumi Fukagawa, and Yoji Takano, and Shigeki Okamoto, and Yayoi Nakagawa, and Eiichi Uchio, and Norihiko Yokoi, and Atsuki Fukushima, and Etsuko Takamura
Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis.
December 1995, Drugs,
Hiroshi Fujishima, and Kazumi Fukagawa, and Yoji Takano, and Shigeki Okamoto, and Yayoi Nakagawa, and Eiichi Uchio, and Norihiko Yokoi, and Atsuki Fukushima, and Etsuko Takamura
Efficacy of Proactive Topical Antihistamine Use in Patients with Seasonal Allergic Conjunctivitis.
December 2022, Advances in therapy,
Hiroshi Fujishima, and Kazumi Fukagawa, and Yoji Takano, and Shigeki Okamoto, and Yayoi Nakagawa, and Eiichi Uchio, and Norihiko Yokoi, and Atsuki Fukushima, and Etsuko Takamura
A comparison of topical levocabastine and sodium cromoglycate in the treatment of pollen-provoked allergic conjunctivitis.
May 1993, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
Hiroshi Fujishima, and Kazumi Fukagawa, and Yoji Takano, and Shigeki Okamoto, and Yayoi Nakagawa, and Eiichi Uchio, and Norihiko Yokoi, and Atsuki Fukushima, and Etsuko Takamura
Efficacy and safety of topical azelastine compared with topical mitomycin C in patients with allergic conjunctivitis.
April 2003, Cornea,
Hiroshi Fujishima, and Kazumi Fukagawa, and Yoji Takano, and Shigeki Okamoto, and Yayoi Nakagawa, and Eiichi Uchio, and Norihiko Yokoi, and Atsuki Fukushima, and Etsuko Takamura
Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05%: a multicenter comparison in patients with seasonal allergic conjunctivitis.
January 2000, Advances in therapy,
Hiroshi Fujishima, and Kazumi Fukagawa, and Yoji Takano, and Shigeki Okamoto, and Yayoi Nakagawa, and Eiichi Uchio, and Norihiko Yokoi, and Atsuki Fukushima, and Etsuko Takamura
Comparative efficacy of topical antihistamines in an animal model of early phase allergic conjunctivitis.
May 2008, Experimental eye research,
Copied contents to your clipboard!